Your session is about to expire
← Back to Search
PET/MRI Imaging for Endometrial Cancer
Study Summary
This trial is investigating whether PET/MRI is more effective than the currently used imaging modalities (CT, or PET/CT) for high-risk endometrial cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 2 trial • 59 Patients • NCT01146054Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is normal, with a GFR over 30.You are afraid of being in small or enclosed spaces.I am a woman aged 18-85 with a specific type of uterine cancer confirmed by biopsy.My cancer is in its early stage with no symptoms of spreading.You have metal implants or fragments in your body that are not safe for the MRI machine we use.I plan to have surgery to reduce tumor size with a specialist at Massachusetts General Hospital.I cannot lie comfortably on my back due to pain or arthritis.I have severe chronic kidney problems.I am undergoing or have recently undergone a liver transplant.I am between 18 and 85 years old.My weight is over 300lbs or my BMI is above 33.
- Group 1: PET/MRI IN ENDOMETRIAL CANCER
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there specific criteria for enrollment into this research project?
"This medical trial is presently recruiting 33 adults aged 18-85 with a histologically confirmed diagnosis of grade 3 endometrioid, serous, carcinosarcoma, undifferentiated or mixed cell carcinoma. To be eligible for the study they must present with no outward signs of metastatic disease (weight loss etc.), receive cytoreductive surgery from Massachusetts General Hospital and have an adequate glomerular filtration rate (>30 mL/min/1.73m2). Even if there has been previous kidney damage which impacts GFR scores but it has since recovered to above 30mL/min then that patient may still"
Are researchers actively seeking participants to join this experiment?
"According to clinicaltrials.gov, the study in question is not presently enrolling patients; it was initially posted on October 1st 2022 and most recently revised on May 21st 2022. However, there are still 3135 other medical trials actively recruiting participants at this time."
Are geriatrics eligible for enrollment in this trial?
"The age range of patients that can enrol in this clinical trial is 18 to 85. There are 80 trials open to minors and 3111 studies specifically for those over the retirement age."
Share this study with friends
Copy Link
Messenger